Phase 1b/2 study of pembrolizumab (pembro) plus platinum/etoposide and platinum/etoposide for neuroendocrine metastatic prostate cancer (NEPC): KEYNOTE-365 cohort I.

Autor: Yu, Evan Y., Joshua, Anthony M., Kramer, Gero, Shore, Neal D., Hu, Haixia, Poehlein, Christian Heinrich, Schloss, Charles, De Bono, Johann S.

Publikováno v: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, pTPS249-TPS249, 235p

KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer.

Autor: Gratzke, Christian, Kwiatkowski, Mariusz, De Giorgi, Ugo, Martins da Trindade, Karine, De Santis, Maria, Armstrong, Andrew J, Niu, Cuizhen, Liu, Yingjie, Poehlein, Christian Heinrich

Publikováno v: Future Oncology; Dec2022, Vol. 18 Issue 37, p4079-4087, 9p

Adjuvant pembrolizumab (pembro) for renal cell carcinoma (RCC) across UCLA Integrated Staging System (UISS) risk groups and disease stage: Subgroup analyses from the KEYNOTE-564 study.

Autor: Choueiri, Toni K., Tomczak, Piotr, Park, Se Hoon, Venugopal, Balaji, Ferguson, Tom, Symeonides, Stefan N., Hajek, Jaroslav, Chang, Yen-Hwa, Lee, Jae-Lyun, Sarwar, Naveed, Thiery-Vuillemin, Antoine, Gross-Goupil, Marine, Mahave, Mauricio, Haas, Naomi B., Sawrycki, Piotr, Zhang, Tian, Xu, Lei, Imai, Kentaro, Poehlein, Christian Heinrich, Powles, Thomas

Publikováno v: Journal of Clinical Oncology; 2/21/2023 Supplement, Vol. 41, p679-679, 1p

KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer.

Autor: Gratzke C; Department of Urology, University Hospital Freiburg, Hugstetterstr. 55, Freiburg, 79106, Germany., Kwiatkowski M; Szpital Wojewodzki im Mikolaja Kopernika, Chałubińskiego 7, Koszalin, 75-581, Poland., De Giorgi U; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Via Piero Maroncelli, 40, Meldola, 47014, Italy., Martins da Trindade K; Oncocentro, Av. Pontes Vieira, 2551, Ceara, 60135-237, Brazil., De Santis M; Charite Universitaetsmedizin, Charitépl. 1, Berlin, 10117, Germany.; Department of Urology, Medical University of Vienna, Spitalgasse 23, Vienna, 1090, Austria., Armstrong AJ; Duke Cancer Institute Center for Prostate & Urologic Cancers, Duke University, 20 Duke Medicine Cir, Durham, NC 27710, USA., Niu C; MSD China, Plot B-12, Electronic City West Zone, Chaoyang District, Beijing, 100012, China., Liu Y; Merck & Co., Inc., 90 E Scott Ave, Rahway, NJ 07065, USA., Poehlein CH; Merck & Co., Inc., 90 E Scott Ave, Rahway, NJ 07065, USA.

Publikováno v: Future oncology (London, England) [Future Oncol] 2023 Jan 27. Date of Electronic Publication: 2023 Jan 27.